• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一个大型的年轻女性乳腺癌患者队列中,根据患者年龄的不同,其病理特征和分子表型也不同。

Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.

机构信息

Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, USA.

出版信息

Breast Cancer Res Treat. 2012 Feb;131(3):1061-6. doi: 10.1007/s10549-011-1872-9. Epub 2011 Nov 13.

DOI:10.1007/s10549-011-1872-9
PMID:22080245
Abstract

Prior studies have suggested a higher prevalence of high grade, ER-negative, HER2-positive, and basal-like carcinomas in young women with breast cancer. However, the precise distribution of poor prognostic features in this population remains unclear. We examined the pathologic features and distribution of molecular phenotype in relation to patient age in a large group of young women (≤40 years) with invasive breast cancer. Medical records were reviewed for clinical characteristics, tumor stage, and receptor status. Pathologic features, including those features associated with basal-like carcinomas, were examined by central review. Using tumor grade and biomarker expression, cancers were categorized as luminal A (ER+ and/or PR+ and HER2-, histologic grade 1 or 2); luminal B (ER+ and/or PR+ and HER2+, or ER and/or PR+, HER2- and grade 3); HER2 (ER and PR- and HER2+); and triple negative (ER-, PR-, and HER2-). Among 399 women of ≤40 years, 33% had luminal A tumors, 35% luminal B, 11% HER2 (ER-negative), and 21% triple negative. Compared to published results for all breast cancers, a greater proportion of young women had luminal B tumors, and a lesser proportion had luminal A. There were no significant differences in molecular phenotype, tumor stage or grade among the different age groups of young women. However, this population of young women presented with a different distribution of molecular phenotypes compared to the general population of women with breast cancer. These findings may have implications with regard to the etiology and prognosis of breast cancer in young women.

摘要

先前的研究表明,年轻乳腺癌患者中高级别、雌激素受体阴性、人表皮生长因子受体 2 阳性和基底样癌的比例较高。然而,该人群中不良预后特征的准确分布仍不清楚。我们在一组年轻女性(≤40 岁)中研究了大量年轻女性(≤40 岁)的病理特征和分子表型分布与患者年龄的关系,这些患者患有浸润性乳腺癌。对临床特征、肿瘤分期和受体状态的病历进行了回顾。通过中心审查,对病理特征,包括与基底样癌相关的特征进行了检查。通过肿瘤分级和生物标志物表达,将癌症分为 luminal A 型(ER+和/或 PR+和 HER2-,组织学分级 1 或 2);luminal B 型(ER+和/或 PR+和 HER2+,或 ER 和/或 PR+,HER2-和分级 3);HER2 型(ER 和 PR-和 HER2+);以及三阴性(ER-、PR-和 HER2-)。在 399 名≤40 岁的女性中,33%为 luminal A 型肿瘤,35%为 luminal B 型,11%为 HER2(ER 阴性),21%为三阴性。与所有乳腺癌的发表结果相比,年轻女性中 luminal B 型肿瘤的比例较高,luminal A 型肿瘤的比例较低。不同年龄组的年轻女性之间在分子表型、肿瘤分期或分级方面无显著差异。然而,与乳腺癌一般人群相比,这组年轻女性的分子表型分布不同。这些发现可能对年轻女性乳腺癌的病因学和预后有影响。

相似文献

1
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.在一个大型的年轻女性乳腺癌患者队列中,根据患者年龄的不同,其病理特征和分子表型也不同。
Breast Cancer Res Treat. 2012 Feb;131(3):1061-6. doi: 10.1007/s10549-011-1872-9. Epub 2011 Nov 13.
2
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.使用定量氟-18氟脱氧葡萄糖/正电子发射断层扫描成像参数比较三阴性乳腺癌与雌激素受体阳性/孕激素受体阳性/人表皮生长因子受体2阴性乳腺癌:一种对疾病特征描述可能有用的方法。
Cancer. 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226.
3
Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)的协同表达在低分化乳腺癌中定义了不同的预后亚型。
Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.
4
Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.1999-2004 年加利福尼亚州第二原发乳腺癌的肿瘤标志物表型一致性。
Breast Cancer Res Treat. 2010 Feb;120(1):217-27. doi: 10.1007/s10549-009-0469-z. Epub 2009 Jul 21.
5
Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.晚期乳腺癌中根据免疫组织化学定义的分子亚型的循环肿瘤细胞的预后价值。
Clin Breast Cancer. 2012 Oct;12(5):340-6. doi: 10.1016/j.clbc.2012.07.001.
6
Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.韩国的三阴性乳腺癌——具有独特生物学特性的疾病,不同预后因素对生存的影响也不同。
Breast Cancer Res Treat. 2010 Aug;123(1):177-87. doi: 10.1007/s10549-010-0998-5. Epub 2010 Jun 24.
7
Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.从三阴性乳腺癌和 35 岁以下女性的组织微阵列中,通过差异标记物表达推断乳腺癌的基底上皮表型。
Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.
8
Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.在激素受体阴性浸润性乳腺癌中,基底-HER2表型的生存率低于基底样表型。
Hum Pathol. 2008 Feb;39(2):167-74. doi: 10.1016/j.humpath.2007.06.012. Epub 2007 Nov 28.
9
Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.导管浸润性乳腺癌——与激素受体和Her2/neu癌蛋白免疫组化表达相关的临床病理预后因素
Rom J Morphol Embryol. 2011;52(3 Suppl):1059-64.
10
High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.高发生率和高频率的 LOH 与高级别 HER2 和三阴性乳腺癌的侵袭性特征相关。
Breast Cancer. 2012 Apr;19(2):161-9. doi: 10.1007/s12282-010-0232-7. Epub 2010 Nov 10.

引用本文的文献

1
Proteogenomic characterization of invasive breast tumors in young women.年轻女性浸润性乳腺癌的蛋白质基因组特征分析
NPJ Breast Cancer. 2025 Aug 18;11(1):94. doi: 10.1038/s41523-025-00793-0.
2
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk.芳香化酶抑制剂、他莫昔芬及卵巢功能抑制在复发风险增加的绝经前激素受体阳性、HER2阴性早期乳腺癌患者中的真实世界应用情况
Breast. 2025 Jun;81:104458. doi: 10.1016/j.breast.2025.104458. Epub 2025 Mar 22.
3
ASO Author Reflections: Personal Insights and Reflections on the Burden of Breast Cancer Among Adolescents and Young Adults.
美国骨科学会(ASO)作者反思:关于青少年和青年乳腺癌负担的个人见解与思考
Ann Surg Oncol. 2025 Apr;32(4):2601-2602. doi: 10.1245/s10434-024-16858-6. Epub 2025 Feb 6.
4
Frequency of somatic and germline variants of predisposition genes in young Chinese women with breast cancer.中国年轻乳腺癌女性中易患基因的体细胞和生殖系变异频率。
Breast Cancer Res Treat. 2025 Apr;210(3):635-644. doi: 10.1007/s10549-024-07602-5. Epub 2025 Jan 5.
5
Analysis the Burden of Breast Cancer Among Adolescents and Young Adults Using the Global Burden of Disease 2021.利用《2021年全球疾病负担》分析青少年和青年成人中的乳腺癌负担。
Ann Surg Oncol. 2025 Mar;32(3):2056-2069. doi: 10.1245/s10434-024-16648-0. Epub 2024 Dec 12.
6
Hormone Receptor Positive Breast Cancer in Young Women: A Review.年轻女性激素受体阳性乳腺癌:综述
J Surg Oncol. 2025 Mar;131(4):580-586. doi: 10.1002/jso.27963. Epub 2024 Oct 29.
7
A retrospective analysis of clinicopathological characteristics and risk factors for recurrence in young patients with breast cancer.年轻乳腺癌患者临床病理特征及复发危险因素的回顾性分析
Gland Surg. 2024 Jul 30;13(7):1281-1290. doi: 10.21037/gs-24-193. Epub 2024 Jul 18.
8
Expert consensus on diagnosis, treatment and fertility management of young breast cancer patients.青年乳腺癌患者诊断、治疗及生育管理的专家共识
J Natl Cancer Cent. 2021 Feb 25;1(1):23-30. doi: 10.1016/j.jncc.2021.02.001. eCollection 2021 Mar.
9
Helping ourselves, helping others: the Young Women's Breast Cancer Study (YWS) - a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger.帮助自己,帮助他人:年轻女性乳腺癌研究(YWS)-一项多中心前瞻性队列研究,旨在深入了解 40 岁及以下女性诊断出的乳腺癌。
BMJ Open. 2024 Jul 1;14(6):e081157. doi: 10.1136/bmjopen-2023-081157.
10
Effect of young age (below 40 years) on oncologic outcomes in Lebanese patients with breast cancer: a matched cohort study.年轻(<40 岁)对黎巴嫩乳腺癌患者肿瘤学结局的影响:一项匹配队列研究。
BMC Cancer. 2024 May 4;24(1):560. doi: 10.1186/s12885-024-11910-w.